Adaptive Biotechnologies Showcases clonoSEQ MRD Testing in 89 Abstracts at ASH 2025

Reuters

2025/11/24

<a href="https://laohu8.com/S/ADPT">Adaptive Biotechnologies</a> Showcases clonoSEQ MRD Testing in 89 Abstracts at ASH 2025

Adaptive Biotechnologies Corporation announced that its next-generation sequencing-based clonoSEQ® test for measurable residual disease (MRD) assessment will be featured in 89 abstracts, including 36 oral presentations, at the 67th Annual Meeting of the American Society of Hematology $(ASH)$, scheduled for December 6-9, 2025, in Orlando. The abstracts will highlight the use of clonoSEQ MRD testing across a range of blood cancers, including multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma. The presentations will include data on clonoSEQ's role in informing patient treatment decisions in real-world clinical practice and its use in clinical trials for assessing responses to novel therapies. The results will be presented at the upcoming ASH conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9591019-en) on November 24, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2585820464"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2585820464\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2585820464?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-24 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585820464","market":"nz","top_or_hot":-1,"title":"Adaptive Biotechnologies Showcases clonoSEQ MRD Testing in 89 Abstracts at ASH 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ADPT\">Adaptive Biotechnologies</a> Showcases clonoSEQ MRD Testing in 89 Abstracts at ASH 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Adaptive Biotechnologies Corporation announced that its next-generation sequencing-based clonoSEQ® test for measurable residual disease (MRD) assessment will be featured in 89 abstracts, including 36 oral presentations, at the 67th Annual Meeting of the American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a>, scheduled for December 6-9, 2025, in Orlando. The abstracts will highlight the use of clonoSEQ MRD testing across a range of blood cancers, including multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma. The presentations will include data on clonoSEQ's role in informing patient treatment decisions in real-world clinical practice and its use in clinical trials for assessing responses to novel therapies. The results will be presented at the upcoming ASH conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9591019-en) on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adaptive Biotechnologies Showcases clonoSEQ MRD Testing in 89 Abstracts at ASH 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdaptive Biotechnologies Showcases clonoSEQ MRD Testing in 89 Abstracts at ASH 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-24 20:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ADPT\">Adaptive Biotechnologies</a> Showcases clonoSEQ MRD Testing in 89 Abstracts at ASH 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Adaptive Biotechnologies Corporation announced that its next-generation sequencing-based clonoSEQ® test for measurable residual disease (MRD) assessment will be featured in 89 abstracts, including 36 oral presentations, at the 67th Annual Meeting of the American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a>, scheduled for December 6-9, 2025, in Orlando. The abstracts will highlight the use of clonoSEQ MRD testing across a range of blood cancers, including multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma. The presentations will include data on clonoSEQ's role in informing patient treatment decisions in real-world clinical practice and its use in clinical trials for assessing responses to novel therapies. The results will be presented at the upcoming ASH conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9591019-en) on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADPT","symbol_name":"Adaptive Biotechnologies Corp","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL7k0hg2:1","article_id":"2585820464","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585820464","pubTimestamp":1763987415,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Adaptive Biotechnologies Corporation announced that its next-generation sequencing-based clonoSEQ test for measurable residual disease  assessment will be featured in 89 abstracts, including 36 oral presentations, at the 67th Annual Meeting of the American Society of Hematology , scheduled for December 6-9, 2025, in Orlando. The abstracts will highlight the use of clonoSEQ MRD testing across a range of blood cancers, including multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma. The presentations will include data on clonoSEQ's role in informing patient treatment decisions in real-world clinical practice and its use in clinical trials for assessing responses to novel therapies. The results will be presented at the upcoming ASH conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADPT":"Adaptive Biotechnologies Corp","BK4121":"生命科学工具和服务","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4112":"金融交易所和数据","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD"},"translate_title":"Adaptive Biotechnologies在ASH 2025上以89份摘要展示clonoSEQ MRD测试","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ADPT":0.9},"content_text":"Adaptive Biotechnologies Showcases clonoSEQ MRD Testing in 89 Abstracts at ASH 2025\n    \n\n        Adaptive Biotechnologies Corporation announced that its next-generation sequencing-based clonoSEQ® test for measurable residual disease (MRD) assessment will be featured in 89 abstracts, including 36 oral presentations, at the 67th Annual Meeting of the American Society of Hematology $(ASH)$, scheduled for December 6-9, 2025, in Orlando. The abstracts will highlight the use of clonoSEQ MRD testing across a range of blood cancers, including multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma. The presentations will include data on clonoSEQ's role in informing patient treatment decisions in real-world clinical practice and its use in clinical trials for assessing responses to novel therapies. The results will be presented at the upcoming ASH conference.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9591019-en) on November 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}